MA31396B1 - Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes - Google Patents

Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes

Info

Publication number
MA31396B1
MA31396B1 MA32375A MA32375A MA31396B1 MA 31396 B1 MA31396 B1 MA 31396B1 MA 32375 A MA32375 A MA 32375A MA 32375 A MA32375 A MA 32375A MA 31396 B1 MA31396 B1 MA 31396B1
Authority
MA
Morocco
Prior art keywords
inhibitor
active compound
combination therapy
adp receptor
platelet adp
Prior art date
Application number
MA32375A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Pamela B Conley
Patrick Andre
Uma Sinha
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MA31396B1 publication Critical patent/MA31396B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA32375A 2007-05-02 2009-11-26 Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes MA31396B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US91591107P 2007-05-03 2007-05-03
US94792107P 2007-07-03 2007-07-03
US97870007P 2007-10-09 2007-10-09
PCT/US2008/062561 WO2008137787A2 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor

Publications (1)

Publication Number Publication Date
MA31396B1 true MA31396B1 (fr) 2010-05-03

Family

ID=39587017

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32375A MA31396B1 (fr) 2007-05-02 2009-11-26 Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes

Country Status (20)

Country Link
US (2) US20080279845A1 (enExample)
EP (2) EP2586439A1 (enExample)
JP (1) JP5439363B2 (enExample)
KR (1) KR101509829B1 (enExample)
CN (1) CN101686959B (enExample)
AU (1) AU2008247435A1 (enExample)
BR (1) BRPI0811000A2 (enExample)
CA (1) CA2684722A1 (enExample)
CO (1) CO6241105A2 (enExample)
EA (1) EA020045B1 (enExample)
EC (1) ECSP099775A (enExample)
ES (1) ES2467468T3 (enExample)
GT (1) GT200900283A (enExample)
IL (1) IL201826A (enExample)
MA (1) MA31396B1 (enExample)
MX (1) MX2009011755A (enExample)
NZ (2) NZ581324A (enExample)
PT (1) PT2146705E (enExample)
TN (1) TN2009000444A1 (enExample)
WO (1) WO2008137787A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401778C (en) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
BRPI0512273A (pt) 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DK2774925T3 (en) 2005-11-08 2017-02-27 Vertex Pharma Heterocyclic modulators of ATP binding cassette transporters
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008057972A1 (en) * 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
US20080293704A1 (en) * 2007-01-05 2008-11-27 Millennium Pharmaceuticals, Inc. FACTOR Xa INHIBITORS
WO2008127682A2 (en) 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
CN103626744B (zh) 2007-12-07 2016-05-11 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
CA2743639A1 (en) * 2008-11-14 2010-05-20 Patheon Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
JP5796872B2 (ja) 2009-12-17 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の結晶性塩
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
ES2550033T3 (es) * 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
CA2792993A1 (fr) * 2010-01-21 2011-07-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Composition particuliere pour son application comme medicament
SI3246021T1 (sl) * 2010-02-25 2020-03-31 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
EP2555755B2 (en) 2010-04-07 2019-07-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
AR082804A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
PT2691371E (pt) * 2011-03-29 2015-07-20 Sanofi Sa Sal de ácido benzóico de otamixaban
US20150224091A1 (en) * 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
WO2014099694A1 (en) * 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
EP2934537B1 (en) * 2012-12-19 2018-04-04 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US9708308B2 (en) 2012-12-19 2017-07-18 Merck Sharp Dohme Corp. Factor IXa inhibitors
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
US9676723B2 (en) * 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
CN106831553A (zh) * 2015-09-11 2017-06-13 天津科伦药物研究有限公司 贝曲西班或其类似物的制备方法
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
EP3254674A1 (en) * 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
WO2018093695A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440147B1 (en) * 1998-09-03 2002-08-27 Rubicor Medical, Inc. Excisional biopsy devices and methods
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
AU760174B2 (en) 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
DE60040676D1 (de) * 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
CA2401778C (en) * 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
AU2001296305B2 (en) 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
ZA200508481B (en) * 2003-04-09 2007-04-25 Japan Tobacco Inc Heteroaromatic pentacyclic compound and medicinal use thereof
US7294635B2 (en) 2003-10-03 2007-11-13 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
DE602004024910D1 (de) * 2003-10-09 2010-02-11 Millennium Pharm Inc Thioethersubstituierte benzamide als inhibitoren von faktor xa
BRPI0512273A (pt) * 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
EP1807086A1 (en) * 2004-10-25 2007-07-18 Boehringer Ingelheim International GmbH Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
WO2006083924A1 (en) 2005-02-02 2006-08-10 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
US7467697B2 (en) * 2005-10-07 2008-12-23 Ford Global Technologies, Llc Electromagnetic coupling device for engine accessories
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
PT1948608E (pt) * 2005-11-08 2012-05-24 Millennium Pharm Inc Novos sais farmacêuticos e polimorfos de um inibidor do fator xa
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CA2671502C (en) * 2006-12-08 2017-01-24 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
US20080293704A1 (en) * 2007-01-05 2008-11-27 Millennium Pharmaceuticals, Inc. FACTOR Xa INHIBITORS
WO2008127682A2 (en) * 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

Also Published As

Publication number Publication date
NZ581324A (en) 2012-05-25
HK1138765A1 (en) 2010-09-03
JP5439363B2 (ja) 2014-03-12
IL201826A0 (en) 2010-06-16
EP2146705A2 (en) 2010-01-27
CA2684722A1 (en) 2008-11-13
EA200901442A1 (ru) 2010-06-30
MX2009011755A (es) 2010-02-12
TN2009000444A1 (en) 2011-03-31
CN101686959B (zh) 2014-05-07
GT200900283A (es) 2011-10-05
PT2146705E (pt) 2014-05-23
US8946219B2 (en) 2015-02-03
US20080279845A1 (en) 2008-11-13
EP2586439A1 (en) 2013-05-01
CO6241105A2 (es) 2011-01-20
ES2467468T3 (es) 2014-06-12
WO2008137787A3 (en) 2009-02-05
AU2008247435A1 (en) 2008-11-13
EA020045B1 (ru) 2014-08-29
NZ599556A (en) 2013-10-25
IL201826A (en) 2014-08-31
JP2010526103A (ja) 2010-07-29
CN101686959A (zh) 2010-03-31
ECSP099775A (es) 2010-01-29
KR101509829B1 (ko) 2015-04-06
US20110033459A1 (en) 2011-02-10
KR20100023836A (ko) 2010-03-04
BRPI0811000A2 (pt) 2015-01-27
EP2146705B1 (en) 2014-03-05
WO2008137787A2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MA31205B1 (fr) Combinaisons d'agents therapeutiques pour le traitement du cancer
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
EP1605936A4 (en) ARYL-spiro hydantoin-CGRP Receptor Antagonists
WO2004082605A3 (en) Bicyclic anilide spirohydantoin cgrp receptor antagonists
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
EP1606264A4 (en) MONOCYCLIC ANILID SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EP1606286A4 (en) BENZODIAZEPINE SPIROHYDANTOINES AS CGRP RECEPTOR ANTAGONISTS
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
IL182317A0 (en) Cgrp receptor antagonists
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
MA52424B1 (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
NZ597648A (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
MY146947A (en) Antiparasitic agent for fish and method of controlling proliferation of fish parasites